Please login to the form below

Not currently logged in
Email:
Password:

Evotec

This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.

Almirall and Evotec team up in multi-target dermatology alliance

Almirall and Evotec team up in multi-target dermatology alliance

Evotec will oversee drug discovery and pre-clinical development, while Almirall will lead the clinical development and marketing. ... We are looking forward to leveraging the complementary expertise of Evotec and Almirall in order to develop promising

Latest news

More from news
Approximately 17 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    The companies, Abbvie, Astex Pharmaceuticals, Eisai, Johnson &Johnson, Lilly, MSD and Takeda, Evotec and Charles River, participate in research projects alongside academic scientists.

  • A snapshot of… Exscientia A snapshot of… Exscientia

    We’ve also signed numerous major pharma collaborations with companies including Roche, Celgene, Sanofi, GSK and Evotec, estimated to be worth over $1bn in milestones and royalties.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Last month, Johnson &Johnson Innovation, Takeda and Evotec became the latest pharma research groups to join the initiative, alongside existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD. ... We’re excited to welcome Johnson

  • Pharma deals continue to slide Pharma deals continue to slide

    For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%

More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....